Evora Biosciences

Executive Summary

Evora Biosciences is a Paris-based private biotechnology company pioneering immunomodulatory lipopeptides, a novel therapeutic class for autoimmune and inflammatory diseases. Founded in 2018, the company focuses on delivering differentiated outcomes in dermatology, ophthalmology, and respiratory care, both as standalone therapies and as steroid-sparing approaches. By leveraging lipopeptide technology, Evora aims to modulate immune responses with improved selectivity and reduced side effects compared to traditional immunosuppressants. The company is currently in preclinical or early clinical development, with no disclosed funding rounds or valuation, indicating a need for near-term milestones to attract investment. Its innovative platform could address significant unmet needs in chronic inflammatory conditions, but the lack of public pipeline data suggests early-stage risk.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA filing for lead candidate in dermatology70% success
• Q4 2026Topline preclinical efficacy data in respiratory model65% success
• TBDSeries A financing or strategic partnership announcement55% success